10-Q Filing

BNB PLUS CORP. CIK: 744452 Q1 2023

Filing Information

Form Type	10-Q
Accession Number	`0001410578-23-000091`
Period End Date	20221231
Filing Date	20230209
Fiscal Year	2023
Fiscal Period	Q1
XBRL Instance	apdn-20221231x10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 66 Income Statement 38 Cash Flow Statement 48 Stockholders Equity 17

Balance Sheet 66 line items

Line Item	Tag	Value	Unit	Period
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$40.83K	USD	Point-in-time
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$330.85K	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$12.88M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$15.22M	USD	Point-in-time
Accounts receivable, net of allowance of $40,831 and $330,853 at December 31, 2022 and September 30, 2022, respectively	`AccountsReceivableNetCurrent`	$3.07M	USD	Point-in-time
Accounts receivable, net of allowance of $40,831 and $330,853 at December 31, 2022 and September 30, 2022, respectively	`AccountsReceivableNetCurrent`	$4.05M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$477.01K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$602.24K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$924.68K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.06M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$18.33M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$19.94M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	12.91M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$2.22M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	12.91M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.87M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	12.91M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	12.91M	shares	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$99.00K	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$98.99K	USD	Point-in-time
Total assets	`Assets`	$22.27M	USD	Point-in-time
Total assets	`Assets`	$20.30M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$3.06M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$3.62M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$273.88K	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$563.56K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.19M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.33M	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$31.47K	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$31.47K	USD	Point-in-time
Warrants classified as a liability	`CommonWarrantLiabilityNoncurrent`	$5.14M	USD	Point-in-time
Warrants classified as a liability	`CommonWarrantLiabilityNoncurrent`	$7.78M	USD	Point-in-time
Total liabilities	`Liabilities`	$11.14M	USD	Point-in-time
Total liabilities	`Liabilities`	$9.36M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2022 and September 30, 2022, respectively	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2022 and September 30, 2022, respectively	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of December 31, 2022 and September 30, 2022, 12,908,520 shares issued and outstanding as of December 31, 2022 and September 30, 2022	`CommonStockValue`	$12.91K	USD	Point-in-time
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of December 31, 2022 and September 30, 2022, 12,908,520 shares issued and outstanding as of December 31, 2022 and September 30, 2022	`CommonStockValue`	$12.91K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$305.40M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$305.49M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-296.34M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-292.50M	USD	Point-in-time
Applied DNA Sciences, Inc. stockholders' equity:	`StockholdersEquity`	$9.16M	USD	Point-in-time
Applied DNA Sciences, Inc. stockholders' equity:	`StockholdersEquity`	$12.91M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-2.89K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-3.76K	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.39M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$12.91M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$9.16M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.11M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$22.27M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$20.30M	USD	Point-in-time

Income Statement 38 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$4.17M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$5.26M	USD	1 Quarter
Total cost of revenues	`CostOfRevenue`	$2.89M	USD	1 Quarter
Total cost of revenues	`CostOfRevenue`	$3.06M	USD	1 Quarter
Gross profit	`GrossProfit`	$2.38M	USD	1 Quarter
Gross profit	`GrossProfit`	$1.11M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.63M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$4.74M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$971.30K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.08M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$3.60M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$5.82M	USD	1 Quarter
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-1.22M	USD	1 Quarter
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-4.71M	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$273.00	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$3.69K	USD	1 Quarter
Unrealized loss on change in fair value of warrants classified as a liability	`FairValueAdjustmentOfWarrants`	$2.64M	USD	1 Quarter
Unrealized loss on change in fair value of warrants classified as a liability	`FairValueAdjustmentOfWarrants`	-	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-14.61K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$8.85K	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-3.84M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-4.72M	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-3.84M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-4.72M	USD	1 Quarter
Less: Net loss (income) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-874.00	USD	1 Quarter
Less: Net loss (income) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$855.00	USD	1 Quarter
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-4.72M	USD	1 Quarter
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-3.84M	USD	1 Quarter
Net loss per share attributable to common stockholders - basic	`EarningsPerShareBasic`	$-0.63	USD	1 Quarter
Net loss per share attributable to common stockholders - basic	`EarningsPerShareBasic`	$-0.30	USD	1 Quarter
Net loss per share attributable to common stockholders - diluted	`EarningsPerShareDiluted`	$-0.30	USD	1 Quarter
Net loss per share attributable to common stockholders - diluted	`EarningsPerShareDiluted`	$-0.48	USD	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	7.49M	shares	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.91M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	7.49M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.91M	shares	1 Quarter

Cash Flow Statement 48 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-3.84M	USD	1 Quarter
Net loss	`ProfitLoss`	$-4.72M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$320.75K	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$338.92K	USD	1 Quarter
Gain on sale of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	1 Quarter
Gain on sale of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$6.08K	USD	1 Quarter
Unrealized loss on change in fair value of warrants classified as a liability	`FairValueAdjustmentOfWarrants`	$2.64M	USD	1 Quarter
Unrealized loss on change in fair value of warrants classified as a liability	`FairValueAdjustmentOfWarrants`	-	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$1.70M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$93.75K	USD	1 Quarter
Change in provision for bad debts	`ProvisionForDoubtfulAccounts`	$-290.02K	USD	1 Quarter
Change in provision for bad debts	`ProvisionForDoubtfulAccounts`	$10.00K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$1.06M	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$695.91K	USD	1 Quarter
Inventories	`IncreaseDecreaseInInventories`	$-69.30K	USD	1 Quarter
Inventories	`IncreaseDecreaseInInventories`	$-125.23K	USD	1 Quarter
Prepaid expenses and other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$24.27K	USD	1 Quarter
Prepaid expenses and other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-133.37K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-169.99K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-586.24K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$-289.68K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$176.54K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.70M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.38M	USD	1 Quarter
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$45.00K	USD	1 Quarter
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	-	USD	1 Quarter
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	1 Quarter
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$104.69K	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$45.00K	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-104.69K	USD	1 Quarter
Net decrease in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-2.34M	USD	1 Quarter
Net decrease in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-3.81M	USD	1 Quarter
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.75M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$15.22M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.88M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.55M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.75M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$15.22M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.88M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.55M	USD	Point-in-time
Cash paid during period for interest	`InterestPaidNet`	-	USD	1 Quarter
Cash paid during period for interest	`InterestPaidNet`	-	USD	1 Quarter
Cash paid during period for income taxes	`IncomeTaxesPaid`	-	USD	1 Quarter
Cash paid during period for income taxes	`IncomeTaxesPaid`	-	USD	1 Quarter
Property and equipment acquired, and included in accounts payable	`PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable`	$20.62K	USD	1 Quarter
Property and equipment acquired, and included in accounts payable	`PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable`	-	USD	1 Quarter
Issuance of stock options for payment of accrued bonus	`IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus`	-	USD	1 Quarter
Issuance of stock options for payment of accrued bonus	`IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus`	$300.00K	USD	1 Quarter

Stockholders Equity 17 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.39M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$12.91M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$9.16M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.11M	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	12.91M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	12.91M	shares	Point-in-time
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.70M	USD	1 Quarter
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$93.75K	USD	1 Quarter
Options issued in settlement of accrued bonus	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition`	$300.00K	USD	1 Quarter
Net loss	`ProfitLoss`	$-3.84M	USD	1 Quarter
Net loss	`ProfitLoss`	$-4.72M	USD	1 Quarter
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.39M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$12.91M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$9.16M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.11M	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	12.91M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	12.91M	shares	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.